Physician

Sreenivasa Chandana, MD

According to 2025 Medicare claims, Sreenivasa Chandana, MD (NPI: 1972705838) practices hematology/oncology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 49503-2563. Chandana is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Chandana's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 331 traditional Medicare patients, billed 112,275 HCPCS/CPT codes, and received $2,017,508 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,049 prescription claims across 211 beneficiaries totaling $1,794,576 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 14 claims. Open Payments data shows 637 records totaling $5,123,454. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,657,764 and ending at $1,794,576. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $15,647 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	895	165,027	$2,339,237
2016	889	138,426	$2,357,486
2017	591	231,990	$2,046,341
2018	578	189,402	$2,619,342
2019	527	149,492	$2,281,201
2020	398	99,085	$1,625,814
2021	393	120,605	$2,469,875
2022	428	134,138	$2,170,842
2023	367	104,190	$2,065,031
2024	331	112,275	$2,017,508

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	231	1,448	$1,657,764
2016	261	1,523	$2,182,961
2017	285	1,037	$783,465
2018	283	1,227	$1,258,914
2019	231	981	$1,338,140
2020	215	910	$1,161,608
2021	192	831	$1,025,665
2022	182	835	$1,030,055
2023	188	766	$1,285,889
2024	211	1,049	$1,794,576

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	172	$15,048
2016	51	171	$43,272
2017	26	94	$22,273
2018	48	165	$20,255
2019	47	134	$18,662
2020	26	74	$6,391
2021	N/R	32	$2,723
2022	43	107	$3,988
2023	22	66	$20,621
2024	N/R	14	$647

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	123	291	$96
96413	Administration of chemotherapy into vein, 1 hour or less	100	404	$89
80053	Blood test, comprehensive group of blood chemicals	138	622	$10
36415	Insertion of needle into vein for collection of blood sample	143	699	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	139	674	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	18	540	$270,997
Creon	Lipase/Protease/Amylase	71	2,736	$254,183
Nyvepria	Pegfilgrastim-Apgf	23	504	$114,789
Xermelo	Telotristat Etiprate	15	336	$85,198
Eliquis	Apixaban	49	1,770	$32,808

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$647

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$33,212	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	559	$5,090,242	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sreenivasa Chandana, MD?

Tedicare shows public-source Medicare data for Sreenivasa Chandana, MD (NPI 1972705838), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sreenivasa Chandana, MD have ACO affiliation data?

Sreenivasa Chandana, MD is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Sreenivasa Chandana, MD?

Sreenivasa Chandana, MD is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Sreenivasa Chandana, MD have Open Payments data?

Sreenivasa Chandana, MD has 637 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.